|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006823,
umls-concept:C0019993,
umls-concept:C0021270,
umls-concept:C0021311,
umls-concept:C0035173,
umls-concept:C0035235,
umls-concept:C0205197,
umls-concept:C0282116,
umls-concept:C1135241,
umls-concept:C1521725,
umls-concept:C1556116,
umls-concept:C1556117,
umls-concept:C1882071,
umls-concept:C2348557,
umls-concept:C2603343,
umls-concept:C2698872
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2004-9-13
|
|
pubmed:abstractText |
Infants born at 33 through 35 completed weeks of gestation (33-35GA) are at risk for severe respiratory syncytial virus (RSV) infection, and palivizumab prophylaxis lowers hospitalizations for RSV infection by as much as 80%. The 33-35GA cohort comprises 3-5% of annual births; thus expert panels recommend limiting prophylaxis to situations in which frequency or health care impact of RSV infection is high. This study sought to identify independent risk factors for hospitalization for RSV infection.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0891-3668
|
|
pubmed:author |
pubmed-author:AllenUptonU,
pubmed-author:BacheyieGodfrey SGS,
pubmed-author:CaouetteGeorgesG,
pubmed-author:FrenetteLyneL,
pubmed-author:LangleyJoanne MJM,
pubmed-author:LawBarbara JBJ,
pubmed-author:Le SauxNicoleN,
pubmed-author:LebelMarc HMH,
pubmed-author:LeeDavid S CDS,
pubmed-author:MajaesicCarinaC,
pubmed-author:ManziPatriciaP,
pubmed-author:MichaliszynAndreaA,
pubmed-author:MitchellIanI,
pubmed-author:MoisiukSharonS,
pubmed-author:O'BrienKarelK,
pubmed-author:OjahCecilC,
pubmed-author:OnyettHeatherH,
pubmed-author:PaesBoscoB,
pubmed-author:ParisonDianaD,
pubmed-author:RobinsonJoanJ,
pubmed-author:SampalisJohnJ,
pubmed-author:SankaranKoravanagattuK,
pubmed-author:SimmonsBrianB,
pubmed-author:SinghAvash JAJ,
pubmed-author:WaltiHervéH
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
806-14
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15361717-Antibodies, Monoclonal,
pubmed-meshheading:15361717-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:15361717-Canada,
pubmed-meshheading:15361717-Cohort Studies,
pubmed-meshheading:15361717-Female,
pubmed-meshheading:15361717-Gestational Age,
pubmed-meshheading:15361717-Hospitalization,
pubmed-meshheading:15361717-Humans,
pubmed-meshheading:15361717-Infant, Newborn,
pubmed-meshheading:15361717-Infant, Premature,
pubmed-meshheading:15361717-Logistic Models,
pubmed-meshheading:15361717-Male,
pubmed-meshheading:15361717-Multivariate Analysis,
pubmed-meshheading:15361717-Predictive Value of Tests,
pubmed-meshheading:15361717-Pregnancy,
pubmed-meshheading:15361717-Prevalence,
pubmed-meshheading:15361717-Probability,
pubmed-meshheading:15361717-Respiratory Syncytial Virus Infections,
pubmed-meshheading:15361717-Risk Assessment,
pubmed-meshheading:15361717-Severity of Illness Index,
pubmed-meshheading:15361717-Sex Factors,
pubmed-meshheading:15361717-Survival Rate,
pubmed-meshheading:15361717-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.
|
|
pubmed:affiliation |
Department of Pediatrics and Child Health, University of Manitoba and the Winnipeg Health Sciences Center, Winnipeg, Canada. blaw@ms.umanitoba.ca
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
